Skip to content
peptide

Thymosin Alpha-1

strongResearch Use OnlyInjection

28-amino-acid immune peptide from thymus tissue. Strengthens T-cell maturation, boosts natural killer cells, and balances immune response. Tested in 30+ trials, approved in 35+ countries for hepatitis, HIV support, and infections. No serious side effects.


Key facts
Classification
Thymosin Alpha-1 is a 28-amino acid peptide from thymic tissue.
Primary benefits
Immune Support (10/10) · Longevity (5/10) · Inflammation (5/10)
Administration
Injection
Doses studied
1.6-2 mg subq once or twice a week. Standard protocol is 1.6 mg twice weekly for 6-12+ months. You can increase frequency if you're fighting off an acute illness. Consistency matters more than timing.
Evidence strength
Strong — 20 peer-reviewed studies
Stacks well with
Thymalin, BPC-157, LL-37, Selank
Legal status
Research Use Only · not prescribable in US
Quick stats
Type
Peptide
Administration
Injection
Studies referenced
20
Stacks with
5 peptides
Regulatory
Research Use Only
Scientific overview

Thymosin Alpha-1 is a 28-amino acid peptide from thymic tissue. Enhances T-cell maturation, dendritic cell function, and NK cell activity. Modulates TLR2/5/9 signaling and promotes Th1 responses. Approved in 35+ countries for hepatitis B/C, with data spanning 3,000+ patients in controlled trials.

Goal coverage · Thymosin Alpha-1
🛡️ Immune Support10/10
Longevity5/10
🧊 Inflammation5/10
🫃 Gut Health3/10
FIG.1  Modeled goal coverage from reviewed studies. Score out of 10.
Medical oversight strongly recommendedNot safe during pregnancy· 3 contraindications
From our network:Cornerstone Peptide